Plain-English translation of NCT07572383 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether advanced imaging scans can measure how well immunosuppressive medications—such as mycophenolate mofetil, mycophenolate sodium, and/or prednisone—are working to slow lung scarring in people with certain types of interstitial lung disease. Researchers will use two special imaging techniques (a PET scan and an MRI scan) to look at collagen buildup in your lungs before you start the medication and again 12 weeks after starting it. This helps doctors understand whether the treatment is actually preventing or slowing the scarring process.
Currently, doctors don't have a reliable way to quickly measure whether these medications are stopping lung scarring—they usually have to wait months or years for changes to show up on standard imaging. This trial aims to develop better, faster imaging tools that can help doctors know sooner if a treatment is working for each patient.
You likely qualify if…
You likely don't qualify if…
You will have two visits scheduled about 12 weeks apart. At each visit, you'll undergo two advanced imaging scans: a PET scan (similar to a CT scan, using a small amount of radioactive tracer injected into your arm) and an MRI scan (which uses magnetic fields to create detailed pictures of your lungs). The first set of scans will happen before you start your immunosuppressive medication, and the second set will happen 12 weeks after you begin treatment. You'll continue taking your medication as prescribed by your regular doctor throughout the study.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Peter Caravan
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Enrollment target
~15 participants
Started
April 2026
Primary completion
December 2028
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sydney Montesi, MD
Massachusetts General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.